Notably, KP tumors failed to respond to PD-1 blockade, which did not offer additional therapeutic benefits when combined with VEGF blockade in full agreement with a recent study of antiangiogenic, anti-PD-1 and chemotherapy in a KP lung cancer model34. This evidence concerns the gene VEGFA and lung carcinoma.